Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Closing Bell Series
May 14, 2024 16:15 ET
|
Autonomix Medical, Inc.
Live webcast on Thursday, May 16th at 4:00 PM ET THE WOODLANDS, TX, May 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company...
Autonomix to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar
April 24, 2024 09:00 ET
|
Autonomix Medical, Inc.
Live webcast on Wednesday, May 1st at 3:20 PM ET THE WOODLANDS, TX, April 24, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device...
Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker
April 08, 2024 08:30 ET
|
Autonomix Medical, Inc.
Live webcast with members of the Autonomix management team, on Thursday, April 11th at 12:00 PM ET THE WOODLANDS, TX, April 08, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX)...
Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial
February 29, 2024 08:30 ET
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence...
Autonomix Secures Principal Investigators and Completes Clinical Training for First Human Study
February 22, 2024 08:00 ET
|
Autonomix Medical, Inc.
Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Company expects to commence patient enrollment imminently...
Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market
February 16, 2024 08:00 ET
|
Autonomix Medical, Inc.
Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, Feb. ...
Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones
February 14, 2024 08:05 ET
|
Autonomix Medical, Inc.
Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate...
Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain
February 06, 2024 08:50 ET
|
Autonomix Medical, Inc.
First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer On track to commence enrollment in Q1 2024 THE WOODLANDS,...
Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event
February 01, 2024 08:35 ET
|
Autonomix Medical, Inc.
Live moderated webcast with members of the Autonomix management team on Wednesday, February 7th at 10:00 AM ET THE WOODLANDS, TX, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc....
Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024
January 31, 2024 08:45 ET
|
Autonomix Medical, Inc.
THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to...